KRP 203

Drug Profile

KRP 203

Alternative Names: KRP-203

Latest Information Update: 28 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Kyorin Pharmaceutical; Novartis
  • Class Anti-inflammatories
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune disorders; Inflammatory bowel diseases; Transplant rejection
  • Discontinued Cutaneous lupus erythematosus; Ulcerative colitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Nov 2015 Discontinued - Phase-II for Inflammatory bowel disease in Japan (PO) (Kyorin Pipeline, November 2015)
  • 01 Sep 2014 Discontinued - Phase-II for Cutaneous lupus erythematosus in Germany, Greece and Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top